HC Wainwright & Co. Reiterates Buy on Arrowhead Pharma, Maintains $90 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Patrick Trucchio has reiterated a Buy rating on Arrowhead Pharma (NASDAQ:ARWR), maintaining a $90 price target.
May 13, 2024 | 3:28 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Arrowhead Pharma's Buy rating and $90 price target have been reiterated by HC Wainwright & Co., indicating continued confidence in the company's prospects.
The reiteration of a Buy rating and a high price target by a reputable analyst firm like HC Wainwright & Co. typically signals strong confidence in the company's future performance. This can positively influence investor sentiment and potentially lead to an increase in stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100